AstraZeneca Reaches Third Place in Spain on Health Reputation Monitor Ranking
The ninth edition of the Health Reputation Monitor (MRS) confirms AstraZeneca’s strong standing within the Spanish healthcare landscape, placing it in third position among pharmaceutical companies. This independent study surveys the reputation of the entire Spanish health system, including doctors, nurses, patient associations, and health journalists, offering a comprehensive snapshot of stakeholder views and public perception (Source: Health Reputation Monitor, ninth edition).
With a total score of 8,107, AstraZeneca rose one spot compared with the previous year’s edition. Its leadership within the pharmaceutical sector is underscored by the company’s ranking among the top business leaders in the industry and its visibility as a prominent employer in Spain’s life sciences ecosystem, signifying growing trust and recognition in the market (Source: Health Reputation Monitor, ninth edition).
The study highlights a milestone for AstraZeneca as part of its broader strategy in Spain. The country has become a central hub in the company’s global growth plan, noted for its high level of clinical trial activity and its role as a key European base for research and development. The organization emphasizes ongoing collaboration with the wider healthcare ecosystem to advance innovative treatments, improve patient outcomes, and strengthen health system resilience. The focus remains on promoting access to transformative therapies and co-creating solutions that contribute to better health outcomes while safeguarding Spain’s healthcare framework (Source: Health Reputation Monitor, ninth edition).
Within the evaluation, AstraZeneca is recognized as a leader in several treatment areas, including Family and Community Medicine and Nephrology, reflecting its reputation as an innovative firm contributing to the management of high-impact diseases such as chronic kidney disease. The report also draws attention to notable progress in Oncology and Hematology, acknowledging the company’s influence on modern cancer treatment strategies. Among the drugs highlighted as having significant therapeutic impact are Enhertu in oncology, Tezspire in pulmonology, Saphnelo in rheumatology, and Lynparza in urology, illustrating a robust portfolio of medicines across key medical fields (Source: Health Reputation Monitor, ninth edition).
AstraZeneca’s commitment to Spain has deepened with a sizable presence in major cities, now employing more than 1,300 people in Madrid and Barcelona. In 2022, the company conducted roughly 472 clinical studies involving over 4,500 participants and recently opened a new European R&D Center in Barcelona. The center is dedicated to accelerating the development of next-generation therapies across a range of focus areas, including Oncology, Rare Diseases, Cardiovascular, Kidney and Metabolism, Respiratory and Immunology, and Vaccines and Immunotherapies. This expansion aligns with the aim of propelling scientific discovery and translating research into improved patient care while reinforcing Spain’s position in the European life sciences landscape (Source: Health Reputation Monitor, ninth edition).
To prepare the study, the MRS panel evaluated diverse actors within the healthcare system, using data from a broad sample: hospital administrators and managers, doctors, patient associations, health journalists, members of the public health administration, pharmaceutical company executives, and hospital pharmacists. The breadth of input supports a multi-faceted view of reputation, reflecting both clinical impact and organizational performance across Spain’s health sectors (Source: Health Reputation Monitor, ninth edition).